Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 7687 results

  1. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]

    In development [GID-TA11267] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

    In development [GID-NG10419] Expected publication date: 31 March 2025

    NICE guideline
    In development

  4. Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)

    In development [GID-NG10415] Expected publication date: TBC

    NICE guideline
    In development

  5. Obinutuzumab for treating lupus nephritis ID 6420

    Awaiting development [GID-TA11478] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

    In development [GID-TA11384] Expected publication date: 28 January 2025

    Technology appraisal guidance
    In development

  7. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891

    In development [GID-TA11473] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height TSID 12070

    Awaiting development [GID-TA11641] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pridopidine for treating Huntington's disease TSID 12052

    Awaiting development [GID-TA11637] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071

    Awaiting development [GID-TA11634] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486

    Awaiting development [GID-TA11623] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050]

    Awaiting development [GID-TA11628] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development